Ultragenyx Pharmaceutical Inc. $RARE Shares Acquired by Comerica Bank

Comerica Bank lifted its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 41.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 118,422 shares of the biopharmaceutical company’s stock after buying an additional 34,711 shares during the period. Comerica Bank’s holdings in Ultragenyx Pharmaceutical were worth $2,724,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Assetmark Inc. increased its holdings in Ultragenyx Pharmaceutical by 1,706.7% in the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 1,024 shares in the last quarter. Huntington National Bank increased its holdings in Ultragenyx Pharmaceutical by 56.2% in the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 393 shares in the last quarter. Danske Bank A S acquired a new stake in Ultragenyx Pharmaceutical in the 3rd quarter valued at $39,000. Smartleaf Asset Management LLC increased its holdings in Ultragenyx Pharmaceutical by 205.4% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 1,169 shares in the last quarter. Finally, Covestor Ltd increased its holdings in Ultragenyx Pharmaceutical by 26.0% in the 3rd quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 369 shares in the last quarter. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Wedbush reiterated a “neutral” rating and issued a $25.00 price target on shares of Ultragenyx Pharmaceutical in a report on Tuesday, February 17th. The Goldman Sachs Group downgraded Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating and lowered their target price for the company from $61.00 to $25.00 in a research note on Tuesday, March 24th. Guggenheim lowered their target price on Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating for the company in a research note on Monday, January 5th. Barclays lowered their target price on Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating for the company in a research note on Wednesday, April 29th. Finally, Truist Financial upgraded Ultragenyx Pharmaceutical to a “strong-buy” rating in a research note on Wednesday, March 25th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $60.76.

Ultragenyx Pharmaceutical Stock Up 0.2%

Shares of NASDAQ RARE opened at $24.81 on Tuesday. The firm’s 50-day moving average price is $22.50 and its two-hundred day moving average price is $26.96. Ultragenyx Pharmaceutical Inc. has a 52-week low of $18.29 and a 52-week high of $42.37. The stock has a market capitalization of $2.44 billion, a P/E ratio of -4.25 and a beta of 0.39.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). The business had revenue of $207.28 million during the quarter, compared to the consensus estimate of $199.60 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 85.54%.The business’s revenue was up 25.5% on a year-over-year basis. During the same period in the prior year, the business earned ($1.39) EPS. As a group, equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post -4.49 earnings per share for the current year.

Insider Activity at Ultragenyx Pharmaceutical

In other news, CAO Theodore Alan Huizenga sold 1,632 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total transaction of $37,209.60. Following the sale, the chief accounting officer owned 48,670 shares of the company’s stock, valued at approximately $1,109,676. The trade was a 3.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Karah Herdman Parschauer sold 8,135 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $22.80, for a total value of $185,478.00. Following the sale, the executive vice president directly owned 76,346 shares in the company, valued at approximately $1,740,688.80. This trade represents a 9.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 111,178 shares of company stock valued at $2,534,628. Company insiders own 5.20% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.